← Issue №15/ week of Oct 11, 2026/Hepatology

AASLD EXPO: Liver biopsy.

From GI Signals issue №15: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Hepatology guideline · Oct 7, 2026 · Hepatology · IF 18.0

AASLD EXPO: Liver biopsy.

Guideline / reviewbiomarkerguideline
Clinical takeawayConsider liver biopsy for diagnosis, staging, or management of liver disease, selecting the approach (percutaneous, transjugular, or endoscopic ultrasound) based on patient-specific factors such as ascites, coagulopathy, or need for portal pressure measurement.
What it foundLiver biopsy remains essential for diagnosis, staging, and management of liver disease, with percutaneous, transjugular, and endoscopic ultrasound approaches showing similar safety and adequacy.
ContextConfirms the ongoing role of liver biopsy in hepatology, despite advances in noninvasive methods, and highlights newer techniques like endoscopic ultrasound-guided biopsy.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Verna EC … Rockey DC · Hepatology · IF 18.0 · PubMed ↗Permalink
← Read the whole of issue №15 Every paper GI Signals surfaces gets a page like this one. All issues